Vol. 6 No. 2 (2026)
Reimbursement Reviews

Ruxolitinib (Opzelura)

decorative image of the issue cover

Published February 10, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ruxolitinib (Opzelura) 1.5% topical cream.
  • Indication: Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.